KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Long-Term Investments: 2009-2024

Historic Long-Term Investments for Regeneron Pharmaceuticals (REGN) over the last 16 years, with Dec 2024 value amounting to $8.9 billion.

  • Regeneron Pharmaceuticals' Long-Term Investments rose 21.14% to $10.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $10.3 billion, marking a year-over-year increase of 21.14%. This contributed to the annual value of $8.9 billion for FY2024, which is 64.92% up from last year.
  • As of FY2024, Regeneron Pharmaceuticals' Long-Term Investments stood at $8.9 billion, which was up 64.92% from $5.4 billion recorded in FY2023.
  • Regeneron Pharmaceuticals' Long-Term Investments' 5-year high stood at $8.9 billion during FY2024, with a 5-year trough of $3.1 billion in FY2020.
  • Its 3-year average for Long-Term Investments is $7.0 billion, with a median of $6.6 billion in 2022.
  • Its Long-Term Investments has fluctuated over the past 5 years, first soared by 118.08% in 2021, then dropped by 18.13% in 2023.
  • Yearly analysis of 5 years shows Regeneron Pharmaceuticals' Long-Term Investments stood at $3.1 billion in 2020, then soared by 118.08% to $6.8 billion in 2021, then dropped by 3.60% to $6.6 billion in 2022, then fell by 18.13% to $5.4 billion in 2023, then soared by 64.92% to $8.9 billion in 2024.